Relapsed Non-Hodgkin’s Lymphoma
<p>rhTPO combined with chemotherapy and G-CSF for autologous peripheral blood stem cells in patients with refractory/relapsed non-Hodgkin’s lymphoma</p>
... The rhTPO is a full-length glycosylated thrombopoietin prepared from Chinese hamster by recombinant DNA tech- nology, which has a pharmacological effect similar to endo- genous TPO. Both in vitro and in vivo experiments ...
7
Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma – novel and emerging therapies
... in relapsed aggressive lymphomas as a novel therapeutic option in treating patients who could not receive dose escalation of traditional cytotoxic agents due to increased ...in relapsed and refrac- tory ...
19
Update on treatment of follicular non-Hodgkin’s lymphoma: focus on potential of bortezomib
... this was a small, nonrandomized, single-institution study, this trial was notable for interesting laboratory correlates. During cycle 1, subjects received bortezomib alone with the addition of rituximab during cycle 2, ...
13
Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma
... B-cell lymphoma; GCB, germinal center B-cell subtype of DLBCL; HLH, hemophagocytic lymphohistiocytosis; iPi, international Prognostic index; ORR, objective response rate (includes complete and partial responses); ...
11
Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies
... for relapsed/refractory HL (detailed in the “Novel therapeutic approaches for primary refractory and early relapsed HL” section) has been embraced with enthusiasm, because they offer the potential for ...
16
Gene mutations and actionable genetic lesions in mantle cell lymphoma
... cell lymphoma (MCL) is a B-cell, non- Hodgkin’s lymphoma (NHL) with poor ...in relapsed MCL as a single agent and currently considered drug of choice in the treatment of relapsed/ ...
11
Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
... in relapsed/refractory CD30 + non- Hodgkin’s lymphomas ...T-cell lymphoma (AITL; n = 13) and PTCL not otherwise specified (n = 22), and in this study brentuximab vedotin showed antitumor activity in ...
5
<p>Abdominal Lymphocyte-Depleted Hodgkin Lymphoma: A Rare Presentation</p>
... pleomorphic Hodgkin and Reed-Sternberg cells (HRS) with diffuse polymorphic cellular population in a background of widespread fi ...classical Hodgkin lymphoma Stage II (infradiaphragmatic ...
5
Profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma
... for Hodgkin lymphoma (and other CD30-positive malignancies), and achieving maximal tumor ...more relapsed/refrac- tory patients to proceed to successful ...
9
Fundamentals of the Management of Non Hodgkin Lymphoma
... On the other hand, as more patients will be cured with availability of novel therapeutic strategy, late effects of cytotoxic chemotherapy and radiotherapy among long term lymphoma survivors remain a major concern. ...
8
A REVIEW ON BREAST CANCER
... Another technique currently being investigated for local treatment of breast cancer is laser ablation. Laser ablation is a technique that generates heat and subsequently causes cell death and tumor destruction. Laser ...
17
Primary Small B-cell Lymphoma (MALT Lymphoma) at Lingual Tonsil: A Case Report Gaffar Aslan 1* , Tulay Tecimer 2, Sadik Server3 , Fikret Cinar 1 Sefik Igdem 4, Ipek Coban5 and Coskun Tecimer 6
... Little is known about the etiological factors for primary lymphoma of the oral region. Few cases of oral lymphoma have been reported in association with the acquired immunodeficiency syndrome [9]. Another ...
9
Apoptosis inhibition or inflammation: the role of NAIP protein expression in Hodgkin and non-Hodgkin lymphomas compared to non-neoplastic lymph node
... 39 Hodgkin Lymphoma and 23 Non Hodgkin Lymphoma cases in comparison with 39 control samples (30 normal and 9 Reactive Lymphoid Hyperplasia (RLH) lymph nodes) using semi-quantitative ...
9
A rare case of a spontaneously ruptured secondary hepatic malignant lymphoma
... malignant lymphoma might be its hypo-vascularity [4]. Majority of hepatic lymphoma lesions demonstrate minimal to no enhancement on all the phases of contrast-enhanced ...central non-enhancement, ...
6
Genetic markers in a multi-ethnic sample for childhood acute lymphoblastic leukemia risk.
... including Hodgkin lymphoma [26], lung cancer [27], rheumatoid arthritis [28], asthma [29], and ulcerative colitis [30-32]; rs10484561, which has been shown to be a strong risk marker in follicular ...
26
Fertility preservation with successful pregnancy outcome in a patient with transplanted heart and non Hodgkin’s lymphoma – a case report
... On the other hand, fertility and pregnancy in heart transplant patients raise complex issues, considering the high risk for potential maternal and foetal complications [3]. Since the first successful pregnancy after ...
5
Prognostic factors in HIV-positive patients with non-Hodgkin lymphoma: a Peruvian experience
... The majority (72.34%) of the patients included in the study had never received ART prior to their lymphoma treatment. This finding is in contrast to European stud- ies in which the majority of patients are ...
6
<p>The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma</p>
... in relapsed/refractory cHL, leading to accel- erated FDA approval of anti-PD-1 IgG4 mAbs, nivolumab and pembrolizumab, in relapsed/refractory cHL (after failed ASCT in the case of ...
9
An atypical presentation of sporadic ovarian Burkitt’s lymphoma: case report and review of the literature
... Burkitt’s lymphoma is generally defined as a neoplasia with a typical, but not pathognomonic aspect of starry-sky pattern induced by mitotes of macrophages, with neoplastic cells that tend to form pseudoacini, ...
5
Allergic conditions are not associated with the risk of non-Hodgkin’s lymphoma or Hodgkin’s lymphoma: a systematic review and meta-analysis
... One of the advantages of the current study is the large sample size, which increased the statistical power to evaluate the association between allergic conditions and the risk of NHL. However, there are also some ...
10